help button home button Am J Pathol Angiogenesis Meeting
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Askanas, V.
Right arrow Articles by Engel, W. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Askanas, V.
Right arrow Articles by Engel, W. K.
(American Journal of Pathology. 1998;153:1673-1677.)
© 1998 American Society for Investigative Pathology

Commentaries

Does Overexpression of ßAPP in Aging Muscle Have a Pathogenic Role and a Relevance to Alzheimer's Disease?

Clues from Inclusion Body Myositis, Cultured Human Muscle, and Transgenic Mice

Valerie Askanas and W. King Engel

From the Neuromuscular Center, Department of Neurology, University of Southern California School of Medicine, Good Samaritan Hospital, Los Angeles, California


   Introduction
Top
 Introduction
Transgenic Mice
 Questions
 Conclusion
 References
 
In Alzheimer's disease (AD) pathogenesis, an underlying ßAPP/Aß dysmetabolism leading to neuronal toxicity is considered the essential abnormality by most investigators.1-4 Hyperphosphorylation and filamentogenesis of tau into paired helical filaments (PHFs) is also thought to be important5,6 and apolipoprotein E4 genotype is considered an aggravating factor.7 The various hypotheses for sporadic AD (s-AD) acknowledge the milieu of aging brain cells but usually omit consideration of an initial sparking event.

For several years it was presumed that ßAPP/Aß and tau abnormalities occur only in the brain (and its blood vessels in regard to ßAPP/Aß), until ßAPP, Aß, and PHFs containing hyperphosphorylated tau were shown to accumulate pathologically within abnormal muscle fibers of two closely related, progressively disabling muscle diseases, sporadic inclusion-body myositis (s-IBM) and hereditary inclusion-body myopathy (h-IBM).8-10 s-IBM is a disease of aging muscle with clinical onset nearly always at age 50 or older; h-IBM begins clinically at ages 15–30 in young adult muscle.11 The autosomal-recessive form of h-IBM is caused by a yet-undetermined gene on chromosome 9 p1-q1,12,13 not a defect of the ßAPP gene on chromosome 21; in two families with the autosomal-dominant form of h-IBM, no defect of the ßAPP-gene was demonstrable.14 s-IBM is the most common muscle disease in older patients. h-IBM is rather rare, but probably more common than hereditary AD (h-AD).

In s-IBM and h-IBM it was shown that ßAPP-mRNA was overexpressed in muscle fibers15 (but not exclusively; cellular prion protein and its mRNA were also overexpressed).16 Several other "Alzheimer characteristic" proteins, including presenilin-1 and proteins related to oxidative stress, also accumulated within abnormal muscle fibers of s-IBM and h-IBM.11,17,18

Intracellular congophilic amyloid deposits are another characteristic and consistent feature of s-IBM muscle fibers.8,19 In h-IBM they are very rare in younger patients, but their occurrence, especially in autosomal-dominant forms, increases in older patients.11 The intracellular amyloid of the IBMs is of two structural-chemical types: collections of 15- to 21-nm PHFs containing immunoreactive tau (and other components, but not Aß), and collections ("microplaquettes") containing 6- to 10-nm filaments immunoreactive for Aß.11

Because the same proteins accumulate within s- and h-IBM muscle fibers as accumulate in the brains of patients with sporadic and hereditary forms of AD, the muscle and brain diseases might share certain pathogenic steps and knowledge of one disease might help elucidate the other. Cellular aging and evidence of oxidative stress are associated with the IBMs and the ADs. The IBMs and the ADs are both multifactorial and polygenetic. The respective cascades of events leading to the specific form of AD-like IBM muscle fiber degeneration and the similar specific features in AD brain are not understood. Within both the IBM and the AD categories, the pathological phenotypes of sporadic and hereditary forms are very similar, despite the different direct causes being mainly nongenetic versus mainly genetic. Therefore, in each disease category it has been proposed, by our group for the IBMs20,21 and by others for the ADs,22,23 that different etiologies including different genetic defects in the hereditary forms lead to the same upstream step, which then promotes the final common downstream pathogenic cascade of events resulting in the specific cellular deterioration. Moreover, the intracellular pathogenic cascades of the IBMs and the ADs might have strong similarities following determination by yet-unknown factors of the initial tissue selectivity in each category, muscle versus brain.

In both s-IBM and h-IBM, it is of particular interest that individual muscle fibers accumulate N- and C-terminal ßAPP and Aß, and ßAPP-mRNA, before other abnormalities are evident.8-11 We hypothesized that overexpression of ßAPP might be upstream to other cellular abnormalities, including oxidative stress and mitochondrial abnormalities (Figure 1) .21 To test this hypothesis, wild-type full-length 751 ßAPP was overexpressed long-term in cultured normal human muscle. It produced within muscle fibers several aspects of the IBM cellular phenotype, including vacuolization, congophilic amyloid inclusions (as microplaquettes) in a small percentage of muscle fibers, cytoplasmic 6- to 10-nm amyloid-like filaments, nuclear PHFs, mitochondrial cytochrome oxidase deficiency, and mitochondrial morphological abnormalities.24,25



View larger version (24K):
[in this window]
[in a new window]
  		Figure 1. Genetic defects in h-IBM and various factors (including a putative virus) in s-IBM lead to presently unknown mechanisms ["?" box in diagram]. These up-regulate ßAPP transcription, resulting in ßAPP overexpression. In the milieu of aging muscle of s-IBM or of adult muscle of h-IBM, overexpression producing excessive ßAPP (the whole molecule or its Aß fragment) leads to oxidative stress with increased free radicals, which contribute to producing the demonstrated IBM muscle fiber abnormalities. Those abnormalities are either directly associated with oxidative stress or possibly caused by oxidative stress. Perhaps some of the former contribute to producing, directly or indirectly, some of the latter. *, present in virtually all s-IBM patients and in the older h-IBM patients; **, both mRNA.

 

   Transgenic Mice
Top
 Introduction
 Transgenic Mice
Questions
 Conclusion
 References
 
This approach of overexpressing ßAPP in muscle has now been extended in two very interesting studies involving transgenic mice, reported in this issue of the Journal. Fukuchi et al overexpressed a wild-type 99-amino acid C-terminal sequence of ßAPP,26 and Jin et al27 overexpressed a C-terminal 99-amino acid sequence of ßAPP containing the substitution of lysine-612 to valine (K612V) resulting in a {alpha}-secretase-resistant mutation intended to increase Aß production. The groups reached some important parallel conclusions.

(1) Within muscle fibers, some aspects of the IBM pathology were produced, including vacuolization and abnormal intracellular accumulation of C-terminal ßAPP and Aß and intracellular amyloid deposits. Whereas Jin et al reported intracellular thioflavin-s-positive amyloid deposits in one-third of the muscle fibers, Fukuchi et al observed polarized-light congo-red positivity in only a few muscle fibers. It remains to be determined whether this difference is due to use of a different ßAPP sequence, mutant versus wild, to generate the transgenic mice or to different staining techniques to identify amyloid deposits. In IBM muscle fibers, because of the small size of amyloid inclusions, evaluating congo-red staining through polarizing filters is often not satisfactory. Using ultraviolet illumination and Texas-red filters greatly increases detection of congophilic amyloid,28 an approach that might be helpful in further studies of the Fukuchi model.

(2) The muscle abnormalities were evident only in aging mice, not being detectable until the mice were 24 months of age or older. In the transgenic mice generated by Fukuchi et al, possibly there was strain-susceptibility.

Additional interesting findings by Jin et al included amyloid-like 6- to 8-nm fibrils within muscle fibers by electron microscopy that closely resemble those present in IBM, and lymphocytic inflammation comparable to that seen in s-IBM muscle (but usually not in h-IBM). Although in s-IBM the lymphocytic response in muscle can be moderate to prominent, the patients respond only slightly or not at all to anti-dysimmune treatments, suggesting that the major causes of clinical weakness are noninflammatory intracellular malfunctions resulting in muscle-fiber vacuolation and atrophy.29 The results reported by Jin et al now suggest that overexpression of ßAPP can produce, directly or indirectly, a lymphocytic response in aging mouse muscle, raising the possibility that in s-IBM the lymphocytic inflammation might not be a primary phenomenon. (The term "inflammation" in reference to s- and h-AD pathology is used quite differently and denotes a response not of circulating lymphocytes or granulocytes but of local microglia and astrocytes.)

Another abnormality described by Jin et al that is similar to that typical of IBM muscle11,17 is the presence of small, angular, atrophic muscle fibers; in muscle pathology these are usually considered to indicate a denervation component. This feature is especially interesting in view of the recent studies in cultured human muscle fibers demonstrating that experimental overexpression of ßAPP prevents formation of neuromuscular junctions, apparently by rendering those cultured muscle fibers incapable of becoming innervated.30 Cultured h-IBM muscle fibers also were not able to be innervated, possibly due to their demonstrated overexpression of ßAPP/Aß.30 A synaptopathic mechanism of ßAPP/Aß overexpression might also be responsible for denervation (and possibly more subtle synaptic abnormalities) seen in IBM patients in vivo and in the ßAPP-transgenic mouse. Likewise, in AD, ßAPP/Aß overexpression might be a direct intracellular cause of the known synaptic abnormalities, considered by some to be the most important substratum of the dementia.31,32

In summary, overexpression of ßAPP/Aß in transgenic mice and in cultured human muscle produces changes similar to those in IBM muscle. This is the scenario we have hypothesized (Figure 1) .21 In some transgenic mice the changes also included lymphocytic inflammation. That the IBM-like changes in the mice were not due to a nonspecific effect of an overexpressed gene is supported by a previous report indicating that in transgenic mice overexpressing the cellular prion protein gene, there was a morphologically nonspecific myopathy that lacked characteristic features of the IBM phenotype.33


   Questions
Top
 Introduction
 Transgenic Mice
 Questions
Conclusion
 References
 
If overexpression of ßAPP/Aß is a key pathogenic step in the IBMs, several questions become important.

(1) How does excessive ßAPP/Aß cause other changes further downstream in mouse and human muscle? Does it directly or indirectly affect transcription, translation, or protein function of other genes, unleashing a cascade of cellular malfunction? Several of the proteins, including some associated with oxidative stress, that accumulate extrajunctionally within IBM muscle fibers are found in normal human muscle only at the postsynaptic region of the neuromuscular junctions.34 These junctionally concentrated proteins include ßAPP and its mRNA and presenilin-1, but not tau.34 We therefore proposed, as an aspect of the pathogenic cascade, an upstream junctionalization phenomenon involving initial overexpression of a putative junctionalizing master gene (jmg).17,34 The ßAPP/Aß overexpression might either activate a jmg or have a jmg function itself.

(2) If aging of the patient is a key prerequisite for developing either s-IBM or s-AD, in what manner might an aging cellular milieu foster the pathogenic mechanism? This is not known but in general, possible mechanisms, such as more easily induced oxidative stress or mitochondrial dysfunction, might involve decrease of youthful protective influences and/or increase of susceptibility factors.

(3) Are there present within muscle fibers of transgenic mice mitochondrial abnormalities, such as absent cytochrome oxidase activity and ultrastructural distortions and increased markers of oxidative stress, like those found in s-IBM biopsied abnormal muscle fibers11,18,20 and in cultured normal human muscle overexpressing the transferred ßAPP gene?11,24

(4) In s-IBM, what is the initial event activating the putatively ßAPP/Aß -mediated pathogenic cascade? A virus-induced mechanism has been proposed.17,29 Because only a small percent of aging persons develop s-IBM, there could be a human strain-susceptibility to either viral infection or viral-induced expression of ßAPP/Aß (eg, by a viral protein acting directly or indirectly on the enhancer/promoter of the ßAPP gene or on its mRNA) or to consequences thereof. This could be analogous to the possible strain-susceptibility of the transgenic mice proposed by Fukuchi et al and reported previously in relation to Alzheimer models of ßAPP-overexpressing transgenic mice.35,36 Whether a virus might be the initiating spark of s-AD remains to be determined. In contrast to Alzheimer's disease, ApoE4 is not a risk factor for the IBMs,37,38 but an increased frequency of the DRB1 0301/0302 allele corresponding to the DR3 HLA haplotype was reported in two studies.39,40

(5) In the h-IBMs, how might a non-ßAPP gene defect cause ßAPP/Aß overexpression? The same general question applies to the h-AD patients having a non-ßAPP mutation of presenilin-1 or presenilin-2.41,42 A general possibility is that the non-ßAPP mutant gene product might directly or indirectly affect ßAPP/Aß expression and/or processing. For example, presenilin-1 and presenilin-2 mutations lead to overproduction of Aß, as do mutations of ßAPP.1-3,41,42

(6) Is the pathogenesis of the IBMs essentially intracellular? We have been proposing this for several years and suggested an upstream intracellular pathogenic role of overexpressed ßAPP/Aß, through modulation of expression of other genes and induction of the demonstrated oxidative-stress and mitochondrial abnormalities.17,18,20 The ßAPP-overexpressing cultured human muscle and transgenic mice support an upstream role for intracellularly overexpressed ßAPP/Aß. In the IBMs, extracellular amyloid plaques do not form. Even though normal muscle fibers in culture secrete Aß 40 and Aß 42 and those secretions are greatly increased in ßAPP-overexpressing cultured muscle fibers (Xie, McFerrin, Engel, Selkoe, and Askanas, unpublished observations, 1997), medium from the latter is not myotoxic.24,25 In vivo, it is possible that clearance of extracellular Aß is more effective from muscle than from brain.

IBM muscle fiber nuclei do not show apoptotic changes by the TUNEL.43-45 However, in all s-IBM patients, 2–3% of the muscle nuclei manifest at least a few disease-characteristic PHFs in addition to those in the cytoplasm,11 and some autosomal-dominant h-IBM nuclei possess many tau-containing PHFs.46 These indicate a disturbance of nuclear metabolism that could be accompanying malfunction of DNA and/or RNA. The cultured human muscle experimentally overexpressing the ßAPP gene had a few of those intranuclear PHFs.25

By analogy with IBM, we raise the possibility that in AD there might be similar mechanisms of intracellularly overexpressed ßAPP/Aß directly inducing abnormality in neurons to cause the essential damage. Although AD investigators generally have favored an initially extracellular role of Aß toxicity,1-4,31,42 recently some have endorsed intracellular mechanisms.47 Because extracellular Aß experimentally can be neurotoxic,2,4 it is possible that extracellular Aß in AD can exert an additional adverse effect.

In IBM muscle fibers, apolipoprotein-E (ApoE) is pathologically localized on the Aß-containing 6- to 10-nm filaments and the tau-containing PHFs,48 but it has not yet been studied in the IBM transgenic mice. In AD, astrocyte-derived intraneuronal ApoE is considered to aggravate neurotoxicity and to be isoform-dependent, ie, more prominent with ApoE4.7 In both IBM and AD, an ApoE aggravation of cytotoxicity might occur by enhancing intracellular damage caused by overexpressed neuronal ßAPP/Aß. Perhaps ApoE also facilitates formation of intracellular 6- to 10-nm fibrils and PHFs.

An obvious corollary of the hypothetically intracellular mechanisms of IBMs and ADs is that a therapeutic drug must enter or at least modulate the intracellular milieu. The two new transgenic mouse models of IBM, like our ßAPP/Aß-overexpressing human muscle cultures, may now be used to explore intracellular pathogenic mechanisms and proposed treatments of ßAPP/Aß overexpression in muscle fibers.

(7) To support a central role for ßAPP/Aß in the pathogenesis of s- and h-IBM, is more evidence needed in the ßAPP overexpression models involving cultured human muscle and the transgenic mice regarding formation of PHFs, accumulation of tau and other Alzheimer-characteristic proteins, and muscle weakness in the transgenic mice? Such evidence would certainly support the hypothesis. In the ßAPP-overexpressing transgenic mice, the question of hyperphosphorylated tau accumulation was not addressed, and ultrastructural PHFs in muscle were not found. In cultured human muscle overexpressing the transferred ßAPP gene, PHFs like those in s-and h-IBM were present in muscle nuclei but not yet found in the muscle cytoplasm.25 Perhaps longer-cultured, longer-overexpressing, older muscle fibers will also manifest the cytoplasmic tau-containing PHFs typical of the IBMs. It is reported that Aß up-regulates tau protein kinase I (TPK-I), resulting in hyperphosphorylated tau, which can lead to PHF formation49 (Aß-up-regulated TPK-I can also phosphorylate, and thereby inactivate, mitochondrial pyruvate dehydrogenase, resulting in cellular depletion of acetyl CoA and consequently reduced ATP synthesis).49 From another aspect, one can ask whether in IBM and AD the accumulated hyperphosphorylated-tau PHFs contribute early and significantly to cellular malfunction, or are simply diagnostically interesting parallel markers, somewhat later-appearing and themselves relatively harmless? If not critically pathogenic, is PHF formation actually necessary to enhance validity of the models?


   Conclusion
Top
 Introduction
 Transgenic Mice
 Questions
 Conclusion
References
 
The two new reports of muscle abnormality in transgenic mice overexpressing ßAPP provide exciting data and intellectual stimulation for further studies of the intracellular molecular pathogenic mechanisms of ßAPP/Aß, which may relate to both the IBMs and the ADs.


   Footnotes
 
Address reprint requests to Valerie Askanas, MD, PhD, USC Neuromuscular Center, 637 South Lucas Avenue, Los Angeles, CA 90017-1912. E-mail: askanas{at}hsc.usc.edu

Accepted for publication October 1, 1998.


   References
Top
 Introduction
 Transgenic Mice
 Questions
 Conclusion
 References
 

  1. Selkoe DJ: Amyloid ß-protein, and the genetics of Alzheimer's disease. J Biol Chem 1996, 271:18295-18298[Free Full Text]
  2. Selkoe DJ: Alzheimer's disease: genotypes, phenotype, and treatments. Science 1997, 275:630-631[Free Full Text]
  3. Hardy J: The Alzheimer family of diseases: many etiologies, one pathogenesis? Proc Natl Acad Sci USA 1997, 94:2095-2097[Free Full Text]
  4. Geula C, Wu C-K, Saroff D, Lorenzo A, Yuan M, Yankner BA: Aging renders the brain vulnerable to amyloid ß-protein neurotoxicity. Nat Med 1998, 4:827-831[Medline]
  5. Terry RD: The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J Neuropathol Exp Neurol 1996, 55:1023-1025[Medline]
  6. Wisniewski HM, Wegiel J, Kotula L: Some neuropathological aspects of Alzheimer's disease and its relevance to other disciplines. Neuropathol Appl Neurobiol 1996, 22:3-11[Medline]
  7. Roses AD, Saunders AM: ApoE, Alzheimer's disease, and recovery from brain stress. Ann NY Acad Sci 1977, 826:200-212[Abstract/Free Full Text]
  8. Askanas V, Engel WK, Alvarez RB: Light- and electronmicroscopic localization of ß-amyloid protein in muscle biopsies of patients with inclusion-body myositis. Am J Pathol 1992, 141:31-36[Abstract]
  9. Askanas V, Alvarez RB, Engel W: ß-amyloid precursor epitopes in muscle fibers of inclusion-body myositis. Ann Neurol 1993, 34:551-560[Medline]
  10. Askanas V, Engel WK, Bilak M, Alvarez RB, Selkoe DJ: Twisted tubulofilaments of inclusion-body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau. Am J Pathol 1994, 144:177-187[Abstract]
  11. Askanas V, Engel WK: Newest approaches to diagnosis and pathogenesis of sporadic inclusion-body myositis and hereditary inclusion-body myopathies, including molecular-pathologic similarities to Alzheimer disease. Askanas V Serratrice G Engel WK eds. Inclusion-Body Myositis and Myopathies. 1998, :pp 3-78 Cambridge University Press, Cambridge
  12. Mitrani-Rosenbaum S, Argov Z, Blumenfeld A, Seidman CD, Seidman JG: Hereditary inclusion body myopathy maps to chromosome 9p1–q1. Hum Mol Genet 1996, 5:159-163[Abstract/Free Full Text]
  13. Middleton LT, Christodoulou K, Askanas V, Engel WK, McFerrin J, Kyriakides T, Zamba E, Papadopoulou E: Molecular genetics of autosomal-recessive hereditary inclusion-body myopathy (AR-IBM). Ann Neurol 1997, 42:414
  14. Sivakumar K, Cervenáková L, Dalakas MC, Leon-Monzon M, Isaacson SH, Nagle JW, Vasconcelos O, Goldfarb LG: Exons 16, and 17 of the amyloid precursor protein gene in familial inclusion body myopathy. Ann Neurol 1995, 38:267-269[Medline]
  15. Sarkozi E, Askanas V, Johnson SA, Engel WK, Alvarez RB: ß -amyloid precursor protein mRNA is increased in inclusion-body myositis muscle. NeuroReport 1993, 4:815-818[Medline]
  16. Sarkozi E, Askanas V, Engel WK: Abnormal accumulation of prion protein mRNA in muscle fibers of patients with sporadic inclusion-body myositis and hereditary inclusion-body myopathy. Am J Pathol 1994, 145:1280-1284[Abstract]
  17. Askanas V, Engel WK: New advances in the understanding of sporadic inclusion-body myositis and hereditary inclusion-body myopathies. Curr Opin Rheumatol 1995, 7:486-496[Medline]
  18. Askanas V, Engel WK: Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: current concepts of diagnosis and pathogenesis. Curr Opin Rheumatol 1998, 10:530-542[Medline]
  19. Mendell JR, Sahenk Z, Gales T, Paul L: Amyloid filaments in inclusion body myositis. Arch Neurol 1991, 48:1229-1234[Abstract]
  20. Askanas V: New developments in hereditary inclusion-body myopathies. Ann Neurol 1997, 41:421-422[Medline]
  21. Askanas V, Engel WK: Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: diseases of oxidative stress and aging? Arch Neurol 1998, 55:915-920[Free Full Text]
  22. Lippa CF, Saunders AM, Smith TW, Swearer JM, Drachman DA, Ghetti B, Nee L, Pulaski-Salo, Dickson D, Robitaille Y, Bergeron C, Crain B, Benson MD, Farlow M, Hyman BT, St. George-Hyslop P, Roses AD, Pollen DA: Familial and sporadic Alzheimer's disease: neuropathology cannot exclude a final common pathway. Neurology 1996, 46:406-412[Abstract/Free Full Text]
  23. Hyman BT: Alzheimer's disease or Alzheimer's diseases? clues from molecular epidemiology. Ann Neurol 1996, 40:135-136[Medline]
  24. Askanas V, McFerrin J, Baqué S, Alvarez RB, Sarkozi E, Engel WK: Transfer of ß-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. Proc Natl Acad Sci USA 1996, 93:1314-1319[Abstract/Free Full Text]
  25. Askanas V, McFerrin J, Alvarez RB, Baqué S, Engel WK: ßAPP gene transfer into cultured human muscle induces inclusion-body myositis aspects. NeuroReport 1997, 8:2155-2158[Medline]
  26. Fukuchi K-I, Pham D, Hart M, Li L, Lindsey JR: Amyloid-ß deposition in skeletal muscle of transgenic mice: possible model of inclusion body myopathy. Am J Pathol 1998, 153:XXX-XXX
  27. Jin L-W, Hearn MG, Ogburn CE, Dang N, Nochlin D, Ladiges WC, Martin GM: Transgenic mice over-expressing the C-99 fragment of ß PP with an {alpha}-secretase site mutation develop a myopathy similar to human inclusion body myositis. Am J Pathol 1998, 153:XXX-XXX
  28. Askanas V, Engel WK, Alvarez RB: Enhanced detection of congo-red-positive amyloid deposits in muscle fibers of inclusion-body myositis and brain of Alzheimer disease using fluorescence technique. Neurology 1993, 43:1265-1267
  29. Engel WK, Askanas V: Treatment of inclusion-body myositis and hereditary inclusion-body myopathy with reference to pathogenic mechanisms. Personal experience. Askanas V Serratrice G Engel WK eds. Inclusion-Body Myositis and Myopathies. 1998, :pp 351-382 Cambridge University Press, Cambridge
  30. McFerrin J, Engel WK, Askanas V: Impaired innervation of cultured human muscle overexpressing ßAPP experimentally and genetically: relevance to inclusion-body myopathies. NeuroReport 1998, 9:3201-3205[Medline]
  31. Masliah E: Biology of disease: role of amyloid precursor protein in the mechanisms of neurodegeneration in Alzheimer's disease. Lab Invest 1997, 77:197-209[Medline]
  32. Hansen LA, Terry RD: Position paper on diagnostic criteria for Alzheimer disease. Neurobiol Aging 1997, 18:S71-S73[Medline]
  33. Westaway D, DeArmond SJ, Cayetano-Canlas J, Groth D, Foster D, Yang S-L, Torchia M, Carlson GA, Prusiner SB: Degeneration of skeletal muscle, peripheral nerves, and the central nervous system in transgenic mice overexpressing wild-type prion proteins. Cell 1994, 76:117-129[Medline]
  34. Askanas V, Engel WK, Alvarez RB: Fourteen newly recognized proteins at the human neuromuscular junctions and their non-junctional accumulation in inclusion-body myositis. Richman DP eds. Myasthenia Gravis and Related Diseases: Disorders of the Neuromuscular Junction, 1998, vol 841.:pp 28-56 Annals of the New York Academy of Sciences, New York
  35. Carlson GA, Borchelt DR, Dake A, Turner S, Danielson V, Coffin JD, Eckman C, Meiners J, Nilsen SP, Younkin SG, Hsiao KK: Genetic modification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice. Hum Mol Genet 1997, 6:1951-1959[Abstract/Free Full Text]
  36. Greenberg BD, Savage MJ, Howland DS, Ali SM, Siedlak SL, Perry G, Siman R, Scott RW: APP transgenesis: approaches toward the development of animal models for Alzheimer disease neuropathology. Neurobiol Aging 1996, 17:153-171[Medline]
  37. Harrington CR, Anderson JR, Chan KK: Apolipoprotein E type E4 allele frequency is not increased in patients with sporadic inclusion-body myositis. Neurosci Lett 1995, 183:35-38[Medline]
  38. Askanas V, Engel WK, Mirabella M, Weisgraber KH, Saunders AM, Roses AD, McFerrin J: Apolipoprotein E alleles in sporadic inclusion-body myositis, and hereditary inclusion-body myopathy. Ann Neurol 1996, 40:264[Medline]
  39. Garlepp MJ: Genetics of the idiopathic inflammatory myopathies. Curr Opin Rhematol 1996, 8:514-520[Medline]
  40. Sivakumar K, Semino-Mora C, Dalakas MC: An inflammatory, familial, inclusion body myositis with autoimmune features and a phenotype identical to sporadic inclusion body myositis: studies in three families. Brain 1997, 120:653-661[Abstract/Free Full Text]
  41. Hardy J: Amyloid, the presenilins, and Alzheimer's disease. TINS 1997, 20:154-159[Medline]
  42. Blacker D, Tanzi RE: The genetics of Alzheimer disease: current status and future prospects. Arch Neurol 1998, 55:294-296[Abstract/Free Full Text]
  43. Mirabella M, Engel WK, Passinetti G, Finch CE, Askanas V: Denervation of adult human muscle fibers induces apoptosis, evidenced by fragmentation of nuclear DNA, and increased expression of the clusterin (ApoJ) gene. Neurology 1996, 46:270[Free Full Text]
  44. Schneider C, Gold R, Dalakas MC, Schmied M, Lassmann H, Toyka KV, Hartung H-P: MHC class I-mediated cytotoxicity does not induce apoptosis in muscle fibers nor in inflammatory T cells: studies in patients with polymyositis, dermatomyositis and inclusion body myositis. J Neuropathol Exp Neurol 1996, 55:1205-1209[Medline]
  45. Behrens L, Bender A, Johnson MA, Hohlfeld R: Cytotoxic mechanisms in inflammatory myopathies. Co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells. Brain 1997, 120:929-938[Abstract/Free Full Text]
  46. Alvarez RB, Simmons Z, Engel WK, Askanas V: New autosomal-dominant inclusion-body myopathy (AD-IBM) with many congophilic muscle nuclei that contain paired-helical filaments (PHFs) composed of phosphorylated tau. Neurology 1998, 50:204
  47. Neve RL, Robakis NK: Alzheimer's disease: a re-examination of the amyloid hypothesis. TINS 1998, 21:15-19[Medline]
  48. Mirabella M, Alvarez RB, Engel WK, Weisgraber KH, Askanas V: Apolipoprotein E and apolipoprotein E messenger RNA in muscle of inclusion-body myositis and myopathies. Ann Neurol 1996, 40:864-872[Medline]
  49. Imahori K, Hoshi M, Ishiguro K, Sato K, Takahashi M, Shiurba R, Yamaguchi H, Takashima A, Uchida T: Possible role of tau protein kinases in pathogenesis of Alzheimer's disease. Neurobiol Aging 1998, 19:S93-S98[Medline]



This article has been cited by other articles:


Home page
 J. Cell Sci.Home page
R. A. Nixon
Autophagy, amyloidogenesis and Alzheimer disease
J. Cell Sci., December 1, 2007; 120(23): 4081 - 4091.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. Morosetti, M. Mirabella, C. Gliubizzi, A. Broccolini, L. De Angelis, E. Tagliafico, M. Sampaolesi, T. Gidaro, M. Papacci, E. Roncaglia, et al.
MyoD expression restores defective myogenic differentiation of human mesoangioblasts from inclusion-body myositis muscle
PNAS, November 7, 2006; 103(45): 16995 - 17000.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. E. Finch
A perspective on sporadic inclusion-body myositis: The role of aging and inflammatory processes
Neurology, January 24, 2006; 66(1_suppl_1): S1 - S6.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
V. Askanas and W. K. Engel
Inclusion-body myositis: A myodegenerative conformational disorder associated with A{beta}, protein misfolding, and proteasome inhibition
Neurology, January 24, 2006; 66(1_suppl_1): S39 - S48.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. B. Rutkove, R. A. Parker, R. A. Nardin, C. E. Connolly, K. J. Felice, and E. M. Raynor
A pilot randomized trial of oxandrolone in inclusion body myositis
Neurology, April 9, 2002; 58(7): 1081 - 1087.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
P. Baron, D. Galimberti, L. Meda, E. Scarpini, G. Conti, F. Cogiamanian, and G. Scarlato
Production of IL-6 by human myoblasts stimulated with A{beta}: Relevance in the pathogenesis of IBM
Neurology, November 13, 2001; 57(9): 1561 - 1565.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. McFerrin, W. K. Engel, and V. Askanas
Cultured inclusion-body myositis muscle fibers do not accumulate {beta}-amyloid precursor protein and can be innervated
Neurology, December 1, 1999; 53(9): 2184 - 2184.
[Abstract] [Full Text]

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Askanas, V.
Right arrow Articles by Engel, W. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Askanas, V.
Right arrow Articles by Engel, W. K.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS